Vera Therapeutics (VERA) “announced its plans to commence a public offering, subject to market and other conditions, to issue and sell $200.0 million of shares of its Class A common stock. All of the shares are being offered by Vera Therapeutics. In connection with the proposed offering, Vera Therapeutics expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of Class A common stock sold in the public offering. J.P. Morgan, Goldman Sachs & Co. LLC, Evercore ISI and Cantor are acting as joint book-running managers for the proposed offering. LifeSci Capital is acting as lead manager for the proposed offering.”
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VERA:
- Vera Therapeutics price target raised to $97 from $75 at Evercore ISI
- Vera Therapeutics price target raised to $73 from $60 at TD Cowen
- Optimistic Buy Rating for Vera Therapeutics Amid Strategic Advancements and Financial Projections
- Vera Therapeutics price target raised to $99 from $52 at JPMorgan
- Strategic Positioning and Market Opportunities Favor Vera Therapeutics: A Buy Recommendation